RT-154
|
Sotalol efficacy in
supraventricular paroxysmal tachyarrhythmias and ventricular heart rhythm disturbances
|
|
|
Gulnara Abuladze, Bondo Kobulia,
Merab Mamatsashvili, Zaza Chapichadze, Natalia Gonjilashvili.
Scientific-Research Institute of Clinical and Experimental Cardiology, Tbilisi,
Georgia
|
|
Abstract
|
|
Background. The aim of our
investigation was an evaluation of antiarrhythmic efficacy of the III class drug sotalol
with the beta-blocking properties in supraventricular paroxysmal tachyar-rhythmias and
ventricular heart rhythm disturbances.
Methods. Eighty-three patients aged 18-75 years old underwent
investigation. Among them 27 pts have diagnosis of supraventricular paroxysmal tachycardia
(SPT), 30 pts paroxysmal atrial fibrillation (PAF) and 26 pts high-gradation ventricular
heart rhythm disturbances and all cases were combined with CAD.
The criteria of antiarrhythmic efficacy of sotalol were 50% decrease of ventricular
extrasystoles (VES) and 90% decrease of pair VES during 24-hr Holter monitoring.
Antiarrhythmic effect of sotalol was considered positive if SPT and PAF disappeared
and could not be provoked by transesophageal left atrium electrostimulation (TE-LAES).
Results. Our results showed that 160 mg sotalol have prevented the
provocation of paroxysms by TE-LAES in 57.2% of pts with SVT. After 240 mg/d sotalol 10-14
days treatment the paroxysms were prevented and unprovoked in 65% of patients.
One hundred and sixty mg sotalol has positive effect in 47.8% of patients with VES by
decreasing the number of VES.
Conclusions. Sotalol is an effective antiarrhythmic agent in
supraventricular paroxysmal tachyarrhythmias and ventricular heart rhythm disturbances by
preventing and decrease of ectopic activity.
|
Key Words
|
|
Treatment of arrhythmias - pharmacological
management
supraventricular paroxysmal tachyarrhythmias, ventricular extrasystols, sotalol, class III
drugs, OA
|
